Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
April 13, 2023
Overcoming Barriers to Drug Development in Children with CKD
Mona Khurana, Gunter F Egger, Lynne Yao, et al.
Kidney Medicine
|
April 4, 2022
Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases
Kelli Collins Damron, Robert Friedman, Lesley A Inker, et al.
Circulation
|
January 7, 2021
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials
Ravi B Patel, Jozine M Ter Maaten, João Pedro Ferreira, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 14, 2020
End Points for Clinical Trials in Primary Hyperoxaluria
Dawn S Milliner, Tracy L McGregor, Aliza Thompson, et al.
Annals of Internal Medicine
|
November 18, 2024
The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial Emulation
Steven T Bird, Kate Gelperin, Elizabeth R Smith, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 21, 2023
End Point Considerations for Clinical Trials in Enteric Hyperoxaluria
Craig B Langman, Dean Assimos, Melanie Blank, et al.
JAMA
|
January 19, 2024
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients
Steven T Bird, Elizabeth R Smith, Kate Gelperin, et al.
Pediatric Research
|
August 31, 2017
Enhancing clinical trial development for pediatric kidney diseases
H William Schnaper, Joseph T Flynn, Coleman Gross, et al.
International Journal of Cardiology
|
May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval
Faiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
JAMA Internal Medicine
|
October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
Cunlin Wang, Robert Kane, Mark Levenson, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Clinical Journal of the American Society of Nephrology : CJASN
|
April 13, 2023
Overcoming Barriers to Drug Development in Children with CKD
Mona Khurana, Gunter F Egger, Lynne Yao, et al.
Kidney Medicine
|
April 4, 2022
Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases
Kelli Collins Damron, Robert Friedman, Lesley A Inker, et al.
Circulation
|
January 7, 2021
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials
Ravi B Patel, Jozine M Ter Maaten, João Pedro Ferreira, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 14, 2020
End Points for Clinical Trials in Primary Hyperoxaluria
Dawn S Milliner, Tracy L McGregor, Aliza Thompson, et al.
Annals of Internal Medicine
|
November 18, 2024
The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial Emulation
Steven T Bird, Kate Gelperin, Elizabeth R Smith, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 21, 2023
End Point Considerations for Clinical Trials in Enteric Hyperoxaluria
Craig B Langman, Dean Assimos, Melanie Blank, et al.
JAMA
|
January 19, 2024
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients
Steven T Bird, Elizabeth R Smith, Kate Gelperin, et al.
Pediatric Research
|
August 31, 2017
Enhancing clinical trial development for pediatric kidney diseases
H William Schnaper, Joseph T Flynn, Coleman Gross, et al.
International Journal of Cardiology
|
May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval
Faiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
JAMA Internal Medicine
|
October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
Cunlin Wang, Robert Kane, Mark Levenson, et al.
Page
of 3